Comparable stake leader
ORBIMED ADVISORS LLC
SEC ownership of Edgewise Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001710072.
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- EWTX on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ORBIMED ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ORBIMED ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001710072
- Issuer location
- Boulder, CO
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Edgewise Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-8 of 50 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
14%
Paradigm Biocapital Advisors LP
9.5%
RA CAPITAL MANAGEMENT, L.P.
7.8%
BlackRock, Inc.
5.5%
Janus Henderson Group Ltd.
5.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
Company · Director, 10%+ Owner
|
14%
from 13D/G
|
$630,516,330
15,518,492 shares
|
— | 30 Jun 2026 |
| Paradigm Biocapital Advisors LP |
13D/G
13F
Company
|
9.5%
|
$493,917,249
10,215,455 shares
|
+$177,649,746 | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
7.8%
|
$405,788,496
8,392,730 shares
|
-$98,426,433 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.5%
from 13D/G
|
$268,415,431
6,606,336 shares
|
— | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
5.5%
|
$197,165,481
5,915,556 shares
|
+$31,204,379 | 31 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
5.1%
|
$265,399,677
5,489,135 shares
|
$0 | 30 Jun 2026 |
| Novo Holdings A/S |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
4.9%
from 13D/G
|
$217,370,500
5,350,000 shares
|
— | 30 Jun 2026 |
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
Company
|
4.4%
from 13D/G
|
$177,714,564
4,373,974 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$18,189,158.
Buys
$199,403
Insiders: 1
Sells
$18,388,561
Insiders: 4
Net
-$18,189,158
Shares: -544,330
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 10,700
Shares: 555,030
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 17,971 | $0 | $785,042 | -$785,042 |
| 3-6 | 0 | 255,230 | $0 | $9,973,465 | -$9,973,465 |
| 6-9 | 0 | 181,829 | $0 | $5,517,604 | -$5,517,604 |
| 9-12 | 10,700 | 100,000 | $199,403 | $2,112,450 | -$1,913,047 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Edgewise Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Novo Holdings A/S
Net 12M change
-$18,189,158
Latest report
01 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Novo Holdings A/S | 10%+ Owner | $95,781,722 | Mixed | 14 Sep 2022 | ||
| Peter A. Thompson | Director, 10%+ Owner | $8,933,533 | Filing P/S | 05 Jun 2026 | ||
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | $8,933,533 | Filing P/S | 03 Apr 2025 | ||
| Kevin Koch | President and CEO, Director | $8,100,303 | -$785,042 | -8.8% | Mixed | 12 Aug 2026 |
| Alan J. Russell | Chief Scientific Officer, Director | $1,836,272 | -$9,993,852 | -84% | Mixed | 12 Aug 2026 |
| Behrad Derakhshan | Chief Business Officer | $1,828,039 | Mixed | 12 Aug 2026 | ||
| R. Michael Carruthers | Chief Financial Officer | $1,591,209 | Mixed | 12 Aug 2025 | ||
| John R. Moore | General Counsel | $1,212,396 | Mixed | 12 Aug 2026 | ||
| Fox Jonathan C. | Director | $1,021,478 | +$199,403 | +24% | Median | 01 Oct 2026 |
| Robert Blaustein | Chief Development Officer | $821,241 | Mixed | 12 Aug 2025 | ||
| Donovan Joanne M. | Cmo | $811,675 | -$4,210,201 | -84% | Mixed | 12 Aug 2026 |
| Semigran Marc | Chief Development Officer | $639,313 | Mixed | 24 Dec 2024 | ||
| Badreddin Edris | Director | $583,500 | -$3,399,466 | -85% | Filing P/S | 05 Jun 2026 |
| Arlene Morris | Director | Mixed | 05 Jun 2026 | |||
| Jonathan D. Root | Director | Mixed | 05 Jun 2026 | |||
| Christopher Nathan Martin | Director | Mixed | 05 Jun 2026 | |||
| Laura Brege | Director | Mixed | 05 Jun 2026 | |||
| Michael Nofi | Chief Financial Officer | Mixed | 12 Aug 2026 |
Recent insider transactions for Edgewise Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Fox Jonathan C. | EWTX | Common Stock | Award | 1.24% | 308 | 25,141 | 01 Oct 2026 | Direct | ||
| Michael Nofi | EWTX | Stock Option (Right to Buy) | Award | 48,750 | 48,750 | 12 Aug 2026 | Direct | |||
| Donovan Joanne M. | EWTX | Stock Option (Right to Buy) | Award | 65,000 | 65,000 | 12 Aug 2026 | Direct | |||
| Alan J. Russell | EWTX | Stock Option (Right to Buy) | Award | 65,000 | 65,000 | 12 Aug 2026 | Direct | |||
| John R. Moore | EWTX | Stock Option (Right to Buy) | Award | 65,000 | 65,000 | 12 Aug 2026 | Direct | |||
| Behrad Derakhshan | EWTX | Stock Option (Right to Buy) | Award | 100,000 | 100,000 | 12 Aug 2026 | Direct | |||
| Kevin Koch | EWTX | Common Stock | Sale | -25.5% | $785,042 | $43.68 | -17,971 | 52,488 | 12 Aug 2026 | Direct |
| Kevin Koch | EWTX | Common Stock | Options Exercise | 130.2% | 39,844 | 70,459 | 12 Aug 2026 | Direct | ||
| Kevin Koch | EWTX | Stock Option (Right to Buy) | Award | 200,000 | 200,000 | 12 Aug 2026 | Direct | |||
| Kevin Koch | EWTX | Restricted Stock Units | Award | 100,000 | 100,000 | 12 Aug 2026 | Direct | |||
| Kevin Koch | EWTX | Restricted Stock Units | Options Exercise | -52.6% | -39,844 | 35,938 | 12 Aug 2026 | Direct | ||
| Alan J. Russell | EWTX | Common Stock | Sale | -89.1% | $7,881,402 | $39.41 | -200,000 | 24,555 | 01 Jul 2026 | Direct |
| Alan J. Russell | EWTX | Common Stock | Options Exercise | 814.5% | 200,000 | 224,555 | 01 Jul 2026 | Direct | ||
| Alan J. Russell | EWTX | Stock Option (Right to Buy) | Options Exercise | -100% | -200,000 | 0 | 01 Jul 2026 | Direct | ||
| Fox Jonathan C. | EWTX | Common Stock | Award | 1.3% | 319 | 24,833 | 01 Jul 2026 | Direct | ||
| Jonathan D. Root | EWTX | Stock Option (Right to Buy) | Award | 16,377 | 16,377 | 05 Jun 2026 | Direct | |||
| Laura A. Brege | EWTX | Stock Option (Right to Buy) | Award | 16,377 | 16,377 | 05 Jun 2026 | Direct | |||
| Peter A. Thompson | EWTX | Stock Option (Right to Buy) | Award | 16,377 | 16,377 | 05 Jun 2026 | Direct | |||
| Morris Arlene | EWTX | Stock Option (Right to Buy) | Award | 16,377 | 16,377 | 05 Jun 2026 | Direct | |||
| Badreddin Edris | EWTX | Stock Option (Right to Buy) | Award | 8,188 | 8,188 | 05 Jun 2026 | Direct | |||
| Badreddin Edris | EWTX | Restricted Stock Units | Award | 5,619 | 5,619 | 05 Jun 2026 | Direct | |||
| Christopher Nathan Martin | EWTX | Stock Options (Right to buy) | Award | 16,377 | 16,377 | 05 Jun 2026 | Direct | |||
| Fox Jonathan C. | EWTX | Stock Option (Right to Buy) | Award | 16,377 | 16,377 | 05 Jun 2026 | Direct | |||
| Donovan Joanne M. | EWTX | Common Stock | Sale | -92% | $1,928,400 | $38.57 | -50,000 | 4,367 | 05 May 2026 | Direct |
| Donovan Joanne M. | EWTX | Common Stock | Options Exercise | 1145% | 50,000 | 54,367 | 05 May 2026 | Direct | ||
| Donovan Joanne M. | EWTX | Stock Option (Right to Buy) | Options Exercise | -40% | -50,000 | 75,000 | 05 May 2026 | Direct | ||
| Donovan Joanne M. | EWTX | Common Stock | Sale | -54.5% | $163,663 | $31.29 | -5,230 | 4,367 | 04 May 2026 | Direct |
| Fox Jonathan C. | EWTX | Common Stock | Award | 1.4% | 339 | 24,514 | 01 Apr 2026 | Direct | ||
| Donovan Joanne M. | EWTX | Common Stock | Sale | -74.9% | $926,095 | $32.31 | -28,662 | 9,597 | 01 Apr 2026 | Direct |
| Donovan Joanne M. | EWTX | Common Stock | Options Exercise | 298.7% | 28,662 | 38,259 | 01 Apr 2026 | Direct | ||
| Donovan Joanne M. | EWTX | Stock Option (Right to Buy) | Options Exercise | -18.6% | -28,662 | 125,000 | 01 Apr 2026 | Direct | ||
| Donovan Joanne M. | EWTX | Common Stock | Sale | -69% | $685,308 | $32.12 | -21,338 | 9,597 | 31 Mar 2026 | Direct |
| Donovan Joanne M. | EWTX | Common Stock | Options Exercise | 222.3% | 21,338 | 30,935 | 31 Mar 2026 | Direct | ||
| Donovan Joanne M. | EWTX | Stock Option (Right to Buy) | Options Exercise | -12.2% | -21,338 | 153,662 | 31 Mar 2026 | Direct | ||
| Donovan Joanne M. | EWTX | Common Stock | Sale | -63% | $506,735 | $30.98 | -16,358 | 9,597 | 27 Mar 2026 | Direct |
| Badreddin Edris | EWTX | Common Stock | Sale | -85.4% | $3,399,466 | $29.44 | -115,471 | 19,820 | 21 Jan 2026 | Direct |
| Badreddin Edris | EWTX | Common Stock | Options Exercise | 582.6% | 115,471 | 135,291 | 21 Jan 2026 | Direct | ||
| Badreddin Edris | EWTX | Stock Option (Right to Buy) | Options Exercise | -100% | -115,471 | 0 | 21 Jan 2026 | Direct | ||
| Fox Jonathan C. | EWTX | Common Stock | Award | 2% | 473 | 24,175 | 02 Jan 2026 | Direct | ||
| Christopher Nathan Martin | EWTX | Stock Options (Right to buy) | Award | 45,150 | 45,150 | 19 Nov 2025 | Direct | |||
| Russell Alan J. | EWTX | Common Stock | Sale | -81% | $2,112,450 | $21.12 | -100,000 | 23,400 | 12 Nov 2025 | Direct |
| Russell Alan J. | EWTX | Common Stock | Options Exercise | 427.4% | 100,000 | 123,400 | 12 Nov 2025 | Direct | ||
| Russell Alan J. | EWTX | Stock Option (Right to Buy) | Options Exercise | -8.02% | -100,000 | 1,147,365 | 12 Nov 2025 | Direct | ||
| Fox Jonathan C. | EWTX | Common Stock | Purchase | 82.3% | $199,403 | $18.64 | 10,700 | 23,702 | 11 Nov 2025 | Direct |
| Michael Nofi | EWTX | Stock Options (Right to buy) | Award | 262,500 | 262,500 | 10 Nov 2025 | Direct | |||
| Michael Nofi | EWTX | Restricted Stock Units | Award | 43,750 | 43,750 | 10 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.